frequency pattern test (fpt) auditec version  (Auditec Inc)

Journal: Infection and Drug Resistance

Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review

doi: 10.2147/IDR.S562107

Figure Lengend Snippet: Summary of enrolled plasma mcfDNA-sequencing studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.

Article Snippet: Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%.

Techniques: Clinical Proteomics, Sequencing

Journal: Infection and Drug Resistance

Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review

doi: 10.2147/IDR.S562107

Figure Lengend Snippet: The refinement strategy of clinical utility of plasma mcfDNA sequencing and prospective. *Co-mNGS Integration (Plasma + Blood Cell DNA): Cost-effectiveness should be further investigated, particularly in resource-limited settings.

Article Snippet: Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%.

Techniques: Clinical Proteomics, Sequencing

Journal: medRxiv

Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

doi: 10.1101/2025.11.05.25339543

Figure Lengend Snippet: Flow diagram depicting patient and sample selection for the comparison of BAL fluid mcfDNA sequencing with the Karius® test and standard of care testing.

Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

Techniques: Selection, Comparison, Sequencing

Journal: medRxiv

Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

doi: 10.1101/2025.11.05.25339543

Figure Lengend Snippet: Additive diagnostic value of BAL fluid mcfDNA sequencing with the Karius® test (KT-BAL) compared to standard of care (SOC) testing in immunocompromised patients with pneumonia. A) Number of organisms across all samples identified by either SOC alone, KT-BAL alone, or both techniques, split by KT-BAL category. B) Organisms identified exclusively by KT-BAL across all samples, split by KT-BAL category.

Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

Techniques: Diagnostic Assay, Sequencing

Journal: medRxiv

Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

doi: 10.1101/2025.11.05.25339543

Figure Lengend Snippet: Patients for whom BAL fluid mcfDNA testing with the Karius® test (KT-BAL) identified Category One or Two organisms missed by standard of care (SOC) had significantly more cumulative intubation days compared to patients where KT-BAL and SOC were concordant for all Category One or Two organisms. Hospital length of stay, ICU length of stay, and ICU mortality were worse in the KT-BAL only group, but these differences were not significant (Mann-Whitney U test for continuous variables, Fisher’s exact test for mortality).

Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

Techniques: MANN-WHITNEY